UBS Group
MRVI icon

UBS Group’s Maravai LifeSciences MRVI Stock Holding History

UBS Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
260,265
+68,467
+36% +$296K ﹤0.01% 5300
2026
Q1 		$543K Sell
191,798
-547,129
-74% -$1.85M ﹤0.01% 6020
2025
Q4 		$2.4M Sell
738,927
-1,660,285
-69% -$5.59M ﹤0.01% 4804
2025
Q3 		$6.89M Sell
2,399,212
-833,072
-26% -$2.13M ﹤0.01% 3696
2025
Q2 		$7.79M Buy
3,232,284
+2,676,831
+482% +$5.63M ﹤0.01% 3377
2025
Q1 		$1.23M Sell
555,453
-1,395,690
-72% -$5.52M ﹤0.01% 5105
2024
Q4 		$10.6M Buy
1,951,143
+1,717,771
+736% +$11.1M ﹤0.01% 2972
2024
Q3 		$1.94M Buy
233,372
+66,349
+40% +$574K ﹤0.01% 4024
2024
Q2 		$1.2M Buy
167,023
+76,955
+85% +$664K ﹤0.01% 4240
2024
Q1 		$781K Sell
90,068
-63,425
-41% -$429K ﹤0.01% 4807
2023
Q4 		$1.01M Buy
153,493
+96,217
+168% +$622K ﹤0.01% 4499
2023
Q3 		$573K Sell
57,276
-84,192
-60% -$924K ﹤0.01% 4554
2023
Q2 		$1.76M Buy
141,468
+27,624
+24% +$373K ﹤0.01% 3660
2023
Q1 		$1.59M Buy
113,844
+23,150
+26% +$332K ﹤0.01% 3667
2022
Q4 		$1.3M Buy
90,694
+6,736
+8% +$106K ﹤0.01% 3826
2022
Q3 		$2.14M Sell
83,958
-9,171
-10% -$230K ﹤0.01% 3100
2022
Q2 		$2.65M Sell
93,129
-8,201
-8% -$260K ﹤0.01% 2906
2022
Q1 		$3.57M Sell
101,330
-20,302
-17% -$681K ﹤0.01% 2882
2021
Q4 		$5.1M Sell
121,632
-17,554
-13% -$711K ﹤0.01% 2792
2021
Q3 		$6.83M Sell
139,186
-11,481
-8% -$560K ﹤0.01% 2357
2021
Q2 		$6.29M Buy
150,667
+80,369
+114% +$3.11M ﹤0.01% 2454
2021
Q1 		$2.5M Buy
70,298
+34,423
+96% +$1.14M ﹤0.01% 3334
2020
Q4 		$1.01M Buy
+35,875
New +$999K ﹤0.01% 4025

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

UBS Group's MRVI Position: Q2 2026 in Review

UBS Group increased its Maravai LifeSciences (MRVI) stake by 36% in Q2 2026, buying an estimated $296K and bringing the position to 260,265 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #5300.

UBS Group first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.6M in Q4 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • UBS Group held 260,265 shares of Maravai LifeSciences worth $1.62M as of Q2 2026.
  • UBS Group bought 68,467 Maravai LifeSciences shares in Q2 2026, an estimated $296K.
  • Maravai LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5300 holding.
  • UBS Group first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • UBS Group's Maravai LifeSciences position peaked at $10.6M in Q4 2024.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.